Creative Financial Designs’s Arbutus Biopharma ABUS Stock Holding History

Creative Financial Designs’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-120	Closed	–	–	466
2019 Q4	$0	Hold	120	–	–	﹤0.01%	529
2019 Q3	$0	Hold	120	–	–	﹤0.01%	619
2019 Q2	$0	Hold	120	–	–	﹤0.01%	547
2019 Q1	$0	Hold	120	–	–	﹤0.01%	554
2018 Q4	$0	Hold	120	–	–	﹤0.01%	576
2018 Q3	$1K	Hold	120	–	–	﹤0.01%	675
2018 Q2	$1K	Hold	120	–	–	﹤0.01%	686
2018 Q1	$1K	Buy	+120	New	+$635	﹤0.01%	637

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Creative Financial Designs's ABUS Position: Q1 2020 in Review

Creative Financial Designs sold out of Arbutus Biopharma (ABUS) in Q1 2020, closing a stake of 120 shares.

Creative Financial Designs first reported a position in ABUS in Q1 2018 and held it in 8 quarters. The position peaked at $1K in Q3 2018. 48 funds tracked by Wall St. Rank hold ABUS as of Q1 2020.

Creative Financial Designs reported no remaining Arbutus Biopharma position as of Q1 2020 after selling out during the quarter.
Creative Financial Designs sold 120 Arbutus Biopharma shares in Q1 2020.
Creative Financial Designs first reported a position in Arbutus Biopharma in Q1 2018 and held it in 8 quarters.
Creative Financial Designs's Arbutus Biopharma position peaked at $1K in Q3 2018.
48 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2020.

Based on Creative Financial Designs's 13F filing for Q1 2020, filed 22 Apr 2020.